{"entity":{"id":"glytr-therapeutics","kind":"company","name":"GlyTR Therapeutics","aka":["GlyTR Therapeutics, Inc."],"tldr":"GlyTR Therapeutics is developing immune treatments that recognise sugar molecules found in large amounts on many kinds of cancer cell, rather than a single protein. Its medicines are still in laboratory and animal testing.","summary":"GlyTR Therapeutics licenses Glycan-dependent T cell Recruiter (GlyTR) technology from the University of California, Irvine, where its founders Michael Demetriou and Raymond Zhou developed it. GlyTR molecules use high-avidity lectin binding to tumour-associated carbohydrate antigens and are made both as bispecific proteins that recruit T cells (GlyTR1 and GlyTR2) and as CAR-T cells; the foundational study was published in Cell in 2025, and the company says it is advancing toward clinical trials. In fiscal year 2026 NCI awarded it USD 1,002,331 under STTR award 4R42CA302415-02 to increase target density for GlyTR immunotherapy.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://glytrtherapeutics.com/"},{"label":"GlyTR Therapeutics: news","url":"https://glytrtherapeutics.com/news/"},{"label":"NIH RePORTER: STTR award 4R42CA302415-02","url":"https://reporter.nih.gov/project-details/11457445"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy","cell-therapy"],"technologies":["t-cell-engager","car-t"],"targets":[],"drugs":["glytr1"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Head office is the city NIH RePORTER gives for the awardee (San Carlos, CA); the company's science page says it is based in Irvine, California. Read on glytrtherapeutics.com and NIH RePORTER on 4 November 2026."],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"hq":"San Carlos, CA","country":"US","companyType":"biotech","website":"https://glytrtherapeutics.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":1002331,"source":"https://reporter.nih.gov/project-details/11457445","note":"NCI STTR award (R42) 4R42CA302415-02: Maximizing GlyTR pan-cancer immunotherapy by enhancing target density"}]},"route":"/companies/glytr-therapeutics/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"glytr1","kind":"drug","name":"GlyTR1","route":"/drugs/glytr1/"}]}}